Why ancillary technologies for stem cell science fail, and what to do about it

Reading time: 8 minutes

Companies building ancillary tools for life sciences (aka TechBio) grapple with life´s messiness. Biology is sensitive, variable, and poorly standardised. Customers are scientists whose workflows run on protocols often developed themselves. For therapeutic applications the regulatory path is one of the most demanding in any industry. And the market, while growing, has yet to settle on which products it actually needs.

This article examines the systemic reasons these companies struggle. Not the generic startup failures of cash mismanagement or co-founder disputes, though those apply too, but the failures that are specific to building technology for biology. Each of the subsequent articles in this series addresses one of these failure modes in detail. Together, they are intended as a practical guide for founders and executives who want to avoid the most common mistakes.

The biology is harder than it looks

A tool that works with purified protein samples, isolated DNA, or standardised chemical reagents operates in a controlled environment. A tool that works with living cells does not. Cells are variable between donors, between passages, between batches of the same reagent, and sometimes between mornings and afternoons in the same laboratory. A cell culture that behaves one way at passage five may behave differently at passage twenty [1].

This variability matters because many ancillary technologies are built and validated against a narrow range of conditions: one cell line, one medium formulation, one operator, one laboratory. When those conditions change, performance can change with them. The tool still functions, but it no longer delivers the consistency that a commercial product requires.

Reproducibility is the first and most fundamental failure mode. It is treated in detail in the companion article on reproducibility, but the core message is straightforward: a product that works in your laboratory under your conditions is a prototype, not a product. The gap between the two is where many companies stall.

Scale-up is a different discipline

Laboratory-scale biology and manufacturing-scale biology obey different rules. Culturing cells in a flat flask is not the same as culturing them in a stirred bioreactor. Mechanical forces, nutrient gradients, oxygen availability, and waste accumulation all change as volumes increase [2]. A process that yields healthy, well-characterised cells at the ten-millilitre scale can produce damaged, heterogeneous populations at ten litres.

The companies most exposed to this risk are those whose technology interfaces with cell expansion, processing, or analysis. If your product depends on cells behaving the way they behave in a research setting, manufacturing reality will introduce variables you did not design for. The physics of fluid dynamics, the biology of mechanical stress, and the economics of consumable cost per unit all converge at scale, and they do not converge gently. The article on scale-up in this series examines these dynamics in detail.

What you measure may not be what matters

Quality control in stem cell science remains an open problem. Current characterisation methods can confirm that a cell expresses the expected surface markers, maintains a normal chromosome count, and differentiates into the expected lineage in laboratory assays. What they cannot reliably detect is functional quality: whether those cells will perform as intended once integrated into a clinical or industrial workflow [3].

For ancillary technology companies, this gap has a direct commercial consequence. If your product claims to improve cell culture, sort cell populations, or monitor cell health, the question becomes: measured against what standard? The International Society for Stem Cell Research (ISSCR) published updated standards for cell characterisation in 2023, but significant gaps remain between what the field measures and what it needs to know [4]. Ancillary tools that address this gap represent one of the largest unmet needs in the sector. But building those tools requires understanding the biology deeply enough to know which measurements are missing, and that understanding is rarer than it should be. The Pillar 1 article on characterisation and quality control examines this in depth, and the Pillar 2 article on characterisation gaps takes the analysis further.

The regulatory path is not optional

Any technology that touches cell-based products intended for human use is subject to Good Manufacturing Practice (GMP) requirements and, increasingly, to the Quality by Design (QbD) framework that regulators expect manufacturers to follow. Many ancillary TechBio companies build products that function well in a research laboratory but are not designed, documented, or validated to meet regulated manufacturing standards [5].

The shift from research-grade to GMP-compliant is not incremental. It involves material traceability, batch documentation, process validation, and environmental monitoring at a level that changes how a product is designed, not just how it is packaged. Companies that defer this transition until a customer requests it often discover that the redesign is effectively starting over. The Pillar 1 article on GMP and Quality by Design provides the foundation for understanding what this transition requires.

The toolchain does not connect

Stem cell workflows involve imaging, cell culture, analytical measurement, data recording, and process control, frequently using instruments from different manufacturers running incompatible software. Data generated at one step may not be accessible at the next. Process parameters optimised in one system may not transfer to another [6].

For the ancillary TechBio company, this fragmentation creates an integration problem. Your tool does not operate in isolation. It has to produce data that the rest of the workflow can consume, or accept inputs in formats the upstream system can deliver. Companies that design their products without accounting for this interoperability end up building instruments that work beautifully in a demonstration but create friction in actual use.

What this series covers

The articles that follow this pillar page each take one of these failure modes and examine it in practical terms: what goes wrong, why it happens, and what can be done differently. They draw on published research, industry data where available, and the operational experience of working at the interface between biology and product development for over four decades.

**Reproducibility as a commercial problem.** Why batch-to-batch variability and operator-dependent outcomes block the path from laboratory proof-of-concept to commercial product, and what it takes to design for consistency from the outset.

**When lab-scale biology meets manufacturing.** The physics and biology of scale-up, from shear stress to nutrient gradients, and where suspension culture and bioreactor platforms lose cell quality.

Characterisation gaps. What current assays miss about stem cell quality, and why the measurements we rely on may not predict real-world performance.

Cryopreservation and supply chain fragility. Cells lose viability and function after freeze-thaw. Batch variability increases with storage. What this means for clinical trials and commercial distribution.

Toolchain fragmentation. Why imaging, culture, and data systems need to communicate, and what interoperability looks like in practice.

The regulatory cliff. Moving from research-grade to GMP-compliant product, and what that transition actually requires in design, documentation, and validation.

Product-market fit. Why tools built for academic novelty rather than industrial workflows fail commercially, and how to test whether your product addresses a real need.

Each article targets the same audience: the founders, CTOs, and scientific officers of TechBio companies who are building ancillary tools for developmental and stem cell science. The biology in these articles is accessible to a professional audience that may not hold a degree in cell biology. The commercial analysis assumes a working knowledge of product development and startup operations. If you need grounding in the underlying biology, the Pillar 1 series provides a working introduction.

References

[1] Borys BS, Dang T, Worden H, et al. Robust bioprocess design and evaluation of commercial media for the serial expansion of human induced pluripotent stem cell aggregate cultures in vertical-wheel bioreactors. Stem Cell Res Ther. 2024;15(1):232. DOI: 10.1186/s13287-024-03819-9

[2] Lee B, Jung S, Hashimura Y, Lee M, Borys BS, Dang T, Kallos MS, Rodrigues CAV, Silva TP, Cabral JMS. Cell Culture Process Scale-Up Challenges for Commercial-Scale Manufacturing of Allogeneic Pluripotent Stem Cell Products. Bioengineering (Basel). 2022 Feb 25;9(3):92. DOI: 10.3390/bioengineering9030092

[3] Setting standards for stem cells. Nat Methods. 2023;20:1267. DOI: 10.1038/s41592-023-02016-5

[4] International Society for Stem Cell Research. Standards for Human Stem Cell Use in Research. 2023. Available from: https://www.isscr.org/basic-research-standards

[5] Borys BS, Roberts EL, Le A, et al. Overcoming bioprocess bottlenecks in the large-scale expansion of high-quality hiPSC aggregates in vertical-wheel stirred suspension bioreactors. Stem Cell Res Ther. 2021;12(1):18. DOI: 10.1186/s13287-020-02109-4

[6] Yehya H, Raudins S, Padmanabhan R, et al. Addressing bioreactor hiPSC aggregate stability, maintenance and scaleup challenges using a design of experiment approach. Stem Cell Res Ther. 2024;15:191. DOI: 10.1186/s13287-024-03802-4

AboutStemCells.Help

StemCells.Help is an advisory consultancy that aids innovation and real-world impact of life science applications built on developmental and stem cell biology. Founded by Dr Paul De Sousa, it draws on over four decades of experience spanning early embryo development, animal cloning, pluripotent stem cell manufacturing, and technology commercialisation. If you build tools for these domains or work in an emerging application where the biology is the enabling technology, StemCells.Help can provide experienced scientific counsel to ground your decisions. To discuss your needs, talk to Paul.

ORCID:0000-0003-0745-2504

Web:stemcells.help